VAXART INC. - COMMON STOCK

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

20 Oct 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

10 Oct 2022 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 08:30:01 By Nasdaq GlobeNewswire

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

01 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

31 Aug 2022 16:30:00 By Nasdaq GlobeNewswire

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

31 Aug 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

25 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

08 Aug 2022 16:01:01 By Nasdaq GlobeNewswire

Vaxart Appoints W. Mark Watson to its Board of Directors

08 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

05 Aug 2022 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

28 Jul 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

27 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

20 Jul 2022 08:30:00 By Nasdaq GlobeNewswire

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

14 Jul 2022 08:00:01 By Nasdaq GlobeNewswire

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

01 Jul 2022 09:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

30 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Vaxart to Host Investor Q&A Webcast

16 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Vaxart Announces Adjournment of Annual Meeting of Stockholders

08 Jun 2022 09:05:00 By Nasdaq GlobeNewswire

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

03 Jun 2022 08:00:00 By Nasdaq GlobeNewswire

Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults

02 Jun 2022 08:30:00 By Nasdaq GlobeNewswire